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SPECIAL ISSUE: THE RAS PATHWAY

RAS-mediated tumor stress adaptation and the targeting
opportunities it presents

ABSTRACT
Cellular stress is known to function in synergistic cooperation with
oncogenic mutations during tumorigenesis to drive cancer
progression. Oncogenic RAS is a strong inducer of a variety of protumorigenic cellular stresses, and also enhances the ability of cells to
tolerate these stresses through multiple mechanisms. Many of these
oncogenic, RAS-driven, stress-adaptive mechanisms have also been
implicated in tolerance and resistance to chemotherapy and to
therapies that target the RAS pathway. Understanding how
oncogenic RAS shapes cellular stress adaptation and how this
functions in drug resistance is of vital importance for identifying new
therapeutic targets and therapeutic combinations to treat RAS-driven
cancers.
KEY WORDS: RAS, Tumor-associated stress, RAS-pathway
targeting, Drug resistance, Stress adaptation

INTRODUCTION

The RAS pathway responds to external growth factors by activating
genes that regulate several biological processes, including cell
growth, division and differentiation. The pathway begins with the
binding of growth factors to their cognate receptor at the cell surface,
leading to the activation of the three isoforms of the small GTPase
RAS (HRAS, KRAS and NRAS). RAS activation initiates multiple
signaling cascades, which culminate in the activation of
transcription factors, such as c-Myc (also known as MYC), c-JUN
(also known as JUN), and ETS and CREB proteins (Chang et al.,
2003). The hyperactivation of the RAS pathway due to the
acquisition of activating mutations in RAS is an initiating event in
malignant transformation; ∼19% of all cancer patients harbor an
activating mutation in one of the RAS genes (Prior et al., 2020). As
such, this prevalent oncogenic driver presents an opportune target in
the treatment of a variety of cancer subtypes. However, inhibiting
the RAS protein in a clinical context has proven challenging for a
variety of reasons (Choi et al., 2019). These include its active site
being tucked away deep inside the protein and thus being
unavailable for small-molecule binding, its high affinity for GTP,
and differences in the structure and hydrolysis rates among specific
RAS mutants (Smith et al., 2013; Cagir and Azmi, 2019).
Several studies have indicated that oncogenic RAS and cellular
stress cooperate in driving tumorigenesis. Cell stress is a doubleedged sword that promotes tumorigenesis but can also lead to cell
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death once a threshold is crossed. Oncogenic RAS is involved in the
induction of a variety of cellular stresses, such as hypoxia (Kikuchi
et al., 2009), metabolic stress (Fritsche-Guenther et al., 2018),
oxidative and endoplasmic reticulum (ER) stress (Liou et al., 2016),
and DNA damage and replication stress (Al Zubaidi et al., 2021;
Maya-Mendoza et al., 2015), which all can promote tumorigenesis.
RAS-driven tumorigenesis, however, is tightly linked to the
activation of stress-adaptive mechanisms, which mitigate against
the levels of these stresses (Alves et al., 2015; Denicola et al., 2011;
Grabocka and Bar-Sagi, 2016). Therefore, RAS-driven, stressadaptive mechanisms can be thought of as vulnerabilities, as the
cancer cell depends on them to survive. As such, understanding how
RAS activates these stress-adaptive pathways, and their role in
tumorigenesis and therapy response, may lead to the discovery of
novel vulnerabilities in RAS mutant cancer cells that can be targeted
in the treatment of these tumors (Fig. 1).
The discovery of small molecules that bind to and inactivate
KRASG12C, a mutant form of RAS present in multiple cancer types,
was an important breakthrough in the field, allowing for a direct
inhibition of one form of aberrant RAS with a promising output in
the clinic (Li et al., 2021a; Jänne et al., 2020; Canon et al., 2019;
Cagir and Azmi, 2019). Nonetheless, MAPK-driven resistance
mechanisms to KRASG12C inhibitors have already been identified,
suggesting that the acquisition of resistance by tumors will
challenge the efficacy of these inhibitors (Ryan et al., 2020; Xue
et al., 2020; Tanaka et al., 2021). As such, combinatorial approaches
that target mechanisms of resistance and RAS pathway regulators
and effectors will likely be required for long-term, efficacious
therapeutic response. Many factors contribute to the resistance
mechanisms that cancers evolve, including tumor and tissue type,
the surrounding microenvironment, the heterogeneous populations
of cancer cells and the direct pressures of a specific therapy. As will
be discussed, resistance mechanisms can be born out of stressadaptive pathways (Fig. 1), as different nodes within such pathways
have been implicated in acquired resistance mechanisms. This route
of resistance may be heightened in cancers driven by oncogenic
RAS, as their survival has been shown to be intricately interwoven
with, and dependent upon, cellular stress responses. Not only can
this potentiate acquired resistance, but the upregulation of stressadaptive responses can also lead to a stress-tolerant phenotype in
which cells have an enhanced survival edge at the start of therapy. In
addition, because tumors consist of a heterogeneous pool of cancer
cell populations, a range of cellular fitness can be present in a single
tumor, which can be specific to a particular stress or environmental
condition. Therefore, the problem of resistance in treating RASdriven cancers is complex, but focusing on common themes of
resistance, such as stress-adaptive pathways, may aid in the
identification of widespread, RAS-driven routes of resistance.
In this Review, we describe the relationship between oncogenic
RAS and various stress-adaptive pathways. In addition, we examine
multiple stress-linked survival and resistance mechanisms present in
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Fig. 1. Targeting stress-adaptive pathways to
enhance chemotherapy and RAS pathwaytargeted therapies. Oncogenic RAS signaling
can both induce cellular stress and inhibit such
stress through the induction of stress-adaptive
pathways, making cancer cells more tolerant to
intrinsic and chemotherapy-derived stresses
and thus providing them with a survival
advantage. Upregulated stress-adaptive
pathways might also contribute to acquired
resistance mechanisms in RAS-driven cancer
cells. When targeting a RAS-driven cancer cell, it
may therefore be necessary to block such
stress-adaptive pathways when providing the
initial therapy, to reduce tolerance and to block
the acquisition of stress-adaptive mechanisms.
GDP, guanosine-5′-diphosphate;
GTP, guanosine-5′-triphosphate.

● Tumor remission
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RAS-driven tumors to better understand how oncogenic RAS
operates as a primary inducer of stress, and in response to stress, to
favor survival. These stress-adaptive mechanisms are pertinent to
understanding therapeutic outcome in the clinic, as resistance is still
a major setback when treating RAS-driven cancer. As new RAS
pathway-targeting therapies arise, the investigation of therapyinduced stress adaptive pathways should be of great importance, as
this may pinpoint appropriate targets that confer resistance for that
specific therapy or cancer type.
RAS-driven adaptations to cellular stress

Oncogenic RAS directly induces various kinds of cellular stress,
and these stress-adaptive responses have been implicated in
promoting tumorigenesis. However, because survival in the face
of stress often relies on the duration and severity of such stress,
oncogenic RAS also upregulates pathways that aid in stress
mitigation. This section will describe how oncogenic RAS
induces stress-adaptive tumor-promoting pathways and keeps
them in check by upregulating other pathways that modulate the
stress intensity.
Adaptation to oxidative stress

Oxidative stress is defined as an imbalance in the levels of free
radicals, and the inability to detoxify free radicals and their harmful
effects. Heightened oxidative stress is a key feature of oncogenic
RAS-driven cancers (Irani et al., 1997; Vafa et al., 2002). The
increased formation of radical oxygen species (ROS), such as
superoxide anion (O2−) and hydrogen peroxide (H2O2), is a
common characteristic of cancer cells (Szatrowski and Nathan,
1991). ROS are generated via the electron transport chain, via the
activation of NADPH oxidases (such as NOX1), or through the
activity of lipoxygenases, among other mechanisms. As they are
major modulators of cell signaling and gene expression, certain
levels of ROS are necessary for cellular function (Chandel et al.,
2000; West et al., 2011). However, ROS are also damaging agents
that can interact with DNA and proteins, cause lipid peroxidation
and lead to apoptosis (Wang et al., 2008). Oxidative stress is kept in
check by the antioxidant program – an intrinsic mechanism by
which cells maintain an appropriate level of free radicals that
opposes the formation and activity of ROS. Antioxidant enzymes,
such as superoxide dismutase (SOD), glutathione peroxidase

GDP

(GPX), catalase and others, break down ROS into non-damaging
molecules (Ighodaro and Akinloye, 2018). Scavenger molecules
also readily react with ROS, reducing the interaction between ROS
and cellular proteins through competition.
Oncogenic RAS increases ROS levels through a variety of
mechanisms, including enhanced activity of NOX proteins, which
produce superoxide. Specifically, RAS elevates ROS levels through
MAPK-mediated transcriptional upregulation of Nox1 (Mitsushita
et al., 2004), p38 (also known as MAPK11)-mediated stabilization
and translocation of the p47phox subunit of Nox1 (Park et al., 2014),
and via COX-2 (also known as PTGS2)-mediated prostaglandin E
production, which generates H2O2 as a byproduct (Maciag et al.,
2004). In oncogenic RAS-driven human pancreatic tumors and in
pancreatic cancer mouse models, the levels of the ROS-inducing
NOX4 correlate positively with tumor progression, indicating a
heightened reliance on ROS during tumorigenesis (Ogrunc et al.,
2014). Oncogenic RAS and mutant BRAF also contribute to the
antioxidant program, as their expression increases the
transcriptional levels of Nrf2 (also known as NFE2L2), a
transcription factor that binds to antioxidant response elements
and promotes the expression of antioxidant genes (Denicola et al.,
2011; Mukhopadhyay et al., 2020). This stress-adaptive mechanism
is pro-tumorigenic, as Nrf2 −/− mouse models of pancreatic cancer
have fewer pancreatic intraepithelial neoplasia (PanINs), which are
also less proliferative and have higher levels of senescence
compared to Nrf2-expressing counterparts (Denicola et al., 2011).
The reduction in proliferation of Nrf2-deficient PanINs can be
rescued by the addition of the antioxidant N-acetyl cysteine,
indicating that this oncogenic RAS-driven antioxidant program
contributes to PanIN formation and progression. In addition to
supporting the antioxidant program, oncogenic RAS inhibits H2O2induced apoptosis (Young et al., 2004). Together, these studies
indicate that oncogenic RAS directly aids in the adaptation to the
oxidative stress it induces, resulting in increased tumorigenesis
in vivo.
Adaptation to metabolic stress

Cancer cells have a higher demand for nutrients and energy relative
to non-transformed cells, to support their rapid levels of growth and
proliferation, and often become stressed in the attempt to satisfy
these metabolic needs. As a cancer cell population grows, it faces
2
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poorer perfusion, leading to the decreased availability of oxygen,
glucose and other nutrients in the microenvironment, further
challenging such metabolic demands (Munir et al., 2019). In
order to survive, cancer cells rewire their metabolism and rely on
increased scavenging mechanisms to support their metabolic needs
(Commisso et al., 2013; Kamphorst et al., 2015; Son et al., 2013;
Humpton et al., 2019). These intracellular metabolic alterations
include changes in amino acid metabolism (Wei et al., 2021), a
shift from oxidative phosphorylation to glycolysis known as the
Warburg effect (Liberti and Locasale, 2016; Vaughn and
Deshmukh, 2008), enhanced lipogenesis (Munir et al., 2019) and
alterations in metabolic enzymes, such as isocitrate dehydrogenase
I and II (Reitman et al., 2011). Many of these changes are universal
across cancer types, but the underlying mechanisms can be
influenced by the oncogenic driver (Munir et al., 2019;
Kamphorst et al., 2013). For example, oncogenic HRAS promotes
elevated lipid uptake, but the expression of constitutively active
myristoylated Akt promotes increased de novo lipid synthesis
(Kamphorst et al., 2013). These metabolic changes have important
implications for cancer progression. For example, the inhibition of
key metabolic enzymes that are upregulated in cancer, such as
lactate dehydrogenase A (LDH-A) and the hexokinase isoform
HK2, delays tumor progression (Krushna et al., 2013; Liu et al.,
2019). The glutaminase inhibitor CB-839, which targets an
essential enzyme involved in glutamine metabolism, has shown
promise in clinical trials, generating an objective response rate of
42% and a disease control rate of 100%, with 42% partial response
and a 58% stable disease, when combined with the tyrosine kinase
inhibitor cabozantinib in patients with metastatic renal cell cancer
(Meric-Bernstam et al., 2019; https://clinicaltrials.gov/ct2/show/
NCT02071862).
Oncogenic RAS influences metabolic stress directly through its
translocation to the mitochondrial membrane and induction of
mitochondrial dysfunction through the inhibition of complex I (Hu
et al., 2012). Oncogenic RAS can also directly promote stressadaptive processes that respond to metabolic stress, including
increased macropinocytosis, autophagy and anabolic processes.
Macropinocytosis, the actin-dependent process of extracellular fluid
engulfment at the plasma membrane, is upregulated in human
pancreatic ductal adenocarcinoma (PDAC) tissue and in KRASG12Cmutant PDAC-derived human cells (Commisso et al., 2013;
Kamphorst et al., 2015). One result of macropinocytosis is the
internalization of extracellular proteins that can be degraded into
amino acids, such as glutamine, on which cancer cells are
metabolically dependent (Commisso et al., 2013; Kamphorst et al.,
2015). The pharmacological inhibition of macropinocytosis in nude
mice that were subcutaneously injected with MIA Paca-2 pancreatic
cancer cells decreased tumor growth and even caused tumor
regression in some animals (Commisso et al., 2013). The
attenuation of tumor growth was specific to pancreatic tumors that
express oncogenic KRAS, suggesting that macropinocytosis is a
critical KRAS-induced survival mechanism (Commisso et al., 2013).
In addition to macropinocytosis, oncogenic RAS can supply
nutrients to metabolically stressed cells by upregulating autophagy
through the Rac1–JNK and the MEK–ERK (also known as
MAP2K–MAPK) pathways (Byun et al., 2009; Wu et al., 2011).
Autophagy is a process by which organelles and macromolecules
are degraded into smaller molecules that can be re-used in metabolic
pathways and is often activated as an adaptation to metabolic stress
(Guo et al., 2011; Poillet-Perez et al., 2015; Meijer et al., 2015). The
overexpression of wild-type or oncogenic KRAS proteins increases
basal levels of autophagy (Alves et al., 2015). Under starvation,

overexpression of oncogenic KRASG13D and KRASG12D in human
non-cancerous colon cells increases levels of autophagy, suggesting
that mutant KRAS plays a specific role in autophagy induction
under stress (Alves et al., 2015). The suppression of autophagy in
KRASG12V-containing colorectal cancer patient-derived SW480
cells through the knockdown of ATG5 and BECN1, which are
involved in autophagosome formation, increases cell death during
starvation, highlighting the importance of autophagy in nutrient
stress adaptation (Alves et al., 2015).
A third mechanism by which oncogenic KRAS combats nutrient
deprivation is through its effect on the expression levels of GOT1
and GLUD1, two major enzymes involved in glutamine metabolism
(Son et al., 2013). Pancreatic cancer cells use GOT1 to fuel the citric
acid cycle while maintaining the redox state of the cell (Son et al.,
2013). KRAS knockdown in multiple PDAC cell lines increases the
mRNA and protein levels of GLUD1 and decreases GOT1 (Son
et al., 2013). This effect was mimicked in vivo, as Got1 mRNA
levels increased and Glud1 mRNA levels decreased with the
induction of KRAS expression in a pancreas-specific doxycyclineactivated oncogenic KRAS-inducible mouse model. GOT1
knockdown led to an approximate sixfold reduction in tumor
volume in this model, indicating that GOT1 aids in tumor growth
(Son et al., 2013).
Oncogenic RAS also activates a selective mitophagy program
that reduces mitochondrial ROS specifically, and redirects glucose
metabolism away from the mitochondria through the increased
expression of BNIP3L (also known as NIX) (Humpton et al., 2019).
BNIP3L is a pro-apoptotic Bcl-2 family member, the interaction of
which at the mitochondrial outer membrane promotes the entry of
lysosomal proteins from the cytoplasm into the mitochondrial
matrix, leading to mitophagy. Mitophagy involves the degradation
of mitochondria through autophagy, often as a result of cellular
stress or damaged mitochondria or, as in this instance, as an output
of oncogenic signaling. RAS-driven mitophagy leads to a reduction
in mitochondrial content. It also leads to a BNIP3L-dependent
decrease in mitochondrial glucose flux and citric acid cycle
intermediates, changes that indicate a channeling of glucose into
aerobic glycolysis or into other anabolic processes (Humpton et al.,
2019). This altered metabolism was hypothesized to lead to an
increased survival advantage for RAS-driven tumors, as BNIP3L
depletion via siRNA reduced the proliferation of KRASG12Dexpressing murine embryonic fibroblasts. In support of this, the
conditional deletion of Bnip3l in pancreata of KC (KRASG12Dexpressing) and KPC (KRASG12D- and p53R172H-expressing)
mouse models resulted in lower-grade PanINs, as well as an
increase in median survival (Humpton et al., 2019). Therefore, RAS
not only induces metabolic stress, but also contributes to multiple
mechanisms that promote survival during metabolic stress.
Adaptation to ER stress

ER stress refers to an increased presence of unfolded proteins within
the ER, which can arise from a variety of cancer-related insults,
including hypoxia, oxidative stress, genomic instability, and
enhanced protein production and secretion (Yang et al., 2014;
Oakes, 2020). ER stress leads to the activation of the unfolded
protein response (UPR), which can be both cytoprotective and
cytotoxic, depending upon how well it can mitigate the
accumulation of unfolded proteins. The UPR contains three main
signaling nodes: inositol-requiring protein 1 (IRE1; also known as
ERN1), activating transcription factor (ATF)-6, and PKR-like
endoplasmic reticulum kinase (PERK; also known as EIF2AK3)
(Yadav et al., 2014). Upon accumulation of misfolded proteins,
3
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these ER transmembrane proteins respond by activating signaling
cascades that promote transcriptional and translational changes,
such as the transient re-localization of specific classes of mRNAs
from the ER into the cytoplasm (Reid et al., 2014), which integrate
to favor either a return to homeostasis or the induction of apoptosis
(Kadowaki and Nishitoh, 2013; Acosta-Alvear et al., 2007; Hetz
et al., 2006).
The UPR plays a significant role in cancer, as markers of this
process are increased or altered across several cancer types (Fig. 2)
(Yadav et al., 2014). In addition, the genetic ablation of Ire1a in
intestinal epithelia-specific Ire1a-knockout mice (Li et al., 2017)
and the mammary gland-specific knockout of Perk in mammary
tumor-prone MMTV-Neu mice (Bobrovnikova-Marjon et al., 2010)
reduce cancer growth and initiation, respectively, and the expression
of PERK has been linked to chemoresistance in colon cancer cells
and in subcutaneous xenograft models of colon cancer in NOD/
SCID mice (Shi et al., 2019). The UPR pathway is upregulated in a
variety of RAS mutant cancers and along the axis of RAS-driven
tumor progression (Blazanin et al., 2017; Denoyelle et al., 2006;
Catanzaro et al., 2014). In human and murine tissue samples of
oncogenic RAS-driven acinar-to-ductal metaplasia (ADM) and
PDAC, the ER stress-sensing protein GRP78 (also known as

HSPA5) is upregulated in ADM and PDAC lesions, whereas little to
no GRP78 is detected in corresponding wild-type samples (Hill
et al., 2012). GRP78 disassociates from the ER transmembrane
proteins IRE1, PERK and ATF6 under ER stress, leading to their
dimerization and activation, which promotes UPR. In terms of
tumorigenicity, GRP78 also contributes to various stem-like
properties of pancreatic cancer cells, such as clonogenicity, selfrenewal and invasion, which translate into a reduced capacity to
initiate tumor formation and to decreased tumor weight in nude
mice subcutaneously injected with pancreatic cancer cells (Dauer
et al., 2019). Although this evidence supports the pro-tumorigenic
properties of ER stress, it is important to note that it can also be antitumorigenic based upon severity and duration, which can explain
the dual nature of oncogenic RAS in inducing or limiting the UPR
(Maurel et al., 2015).
Consistent with the pro-tumorigenic role of ER stress, oncogenic
RAS can directly impact ER stress levels through the activation of
IRE1a via the MEK–ERK pathway (Blazanin et al., 2017). The
expression of oncogenic HRAS in primary murine keratinocytes
increases Ire1a mRNA and protein levels and its phosphorylation,
indicative of the overall IRE1a activation (Blazanin et al., 2017). In
addition, oncogenic RAS induces ER stress indirectly through ROS
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Fig. 2. Oncogenic RAS-driven induction of stress-adaptive mechanisms and current therapies along the signaling axis. Oncogenic RAS induces multiple
stress-adaptive pathways, such as altered (glucose) metabolism, UPR, DDR, autophagy, macropinocytosis and stress granule formation. Canonical oncogenic
RAS signaling, such as the activation of the MEK–ERK1/2 and PI3K–AKT pathways, which directly promote proliferation, is also displayed. There are multiple
drugs in clinical trials that target different nodes within these stress-adaptive and canonical pathways, as shown in red. There are still mutant RAS-driven stressadaptive pathways that have yet to be targeted in the clinic, such as the formation of stress granules. CQ, chloroquine; DDR, DNA damage response;
HCQ, hydroxychloroquine; OxPhos, oxidative phosphorylation; TCA, tricarboxylic acid cycle; UPR, unfolded protein response.
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induction (Park et al., 2014; Mitsushita et al., 2004). As discussed
above, ER stress can result in both cell survival and cell death, and
tumorigenic progression requires the tempering of and/or adaptation
to ER stress. IRE1a activation by oncogenic RAS results in the
splicing of X-box-binding protein 1 (Xbp1), which has been
implicated in stress adaptation during the UPR (Blazanin et al.,
2017; Hollien et al., 2009). ER stress favors this particular activity of
IRE1a, which was shown to be necessary for mutant HRASexpressing cells to proliferate. By contrast, reduced ER stress favors
senescence despite the retention of activated IRE1a. This shows that
both the presence of ER stress and the activation of IRE1a through
oncogenic RAS work together to promote a proliferation-supportive
phenotype. Oncogenic RAS also specifically upregulates proteins
that limit the ER stress response. In patient-derived myeloma cell
lines that were engineered to constitutively express mutant forms of
either KRAS, NRAS or BRAF, the expression of each of these
oncogenes increased the transcription of proteasome 20S subunit
beta 8, 9 and 10 (PSMB8, PSMB9 and PSMB10) (Shirazi et al.,
2020). The transcriptional levels of the assembly chaperone
proteasome maturation protein (POMP) and its upstream regulator
Nrf2, which are required for the cleavage and activation of PSMB8/
9/10, were also increased after the expression of the KRAS, NRAS or
BRAF oncogenes (Shirazi et al., 2020). These results suggest that
oncogenic RAS and BRAF may enhance proteasome capacity,
which could mitigate the activation of the ER stress response
through a reduction in proteotoxic stress. Surprisingly, the
expression of these oncogenes also reduced the transcription of
ATF4 and ATF6, which are involved in the ER stress response,
showing that oncogenic RAS can directly dampen ER stress
signaling as well.

oncogenic RAS to the stress-adaptive mechanisms involved in cell
survival during hypoxia. For example, the expression of oncogenic
KRAS enhances HIF-1α function, and that of oncogenic BRAF
enhances HIF-1α and HIF-2α (also known as EPAS1) function
during hypoxia (Kikuchi et al., 2009). Receptor for advanced
glycation end products (RAGE; also known as AGER), a protein
primarily involved in inflammation, acts as a positive regulator of
HIF-1α through its binding to oncogenic RAS during hypoxia
(Kang et al., 2014). This binding is increased in human pancreatic
cancer cells that express oncogenic RAS compared to a pancreatic
cancer cell line that expresses wild-type RAS, suggesting that the
mutational status of RAS may play a role in such binding (Kang
et al., 2014). When MEK1/2 and AKT are inhibited in a murine
pancreatic tumor cell line, RAGE can no longer activate HIF-1α,
indicating that RAGE activates oncogenic RAS signaling to
promote adaptation to hypoxic conditions (Kang et al., 2014).
Moreover, knocking down RAGE in murine pancreatic tumor cell
lines under hypoxia and knocking it out in KC mice in vivo reduces
phospho-AKT and phospho-ERK1/2 levels (Kang et al., 2014). In
addition to the activation of HIF-1α, oncogenic RAS has been
shown to converge on a hypoxia-induced, stress-adaptive pathway
that targets the tumor suppressor reversion-inducing cysteine-rich
protein with Kazal motifs (RECK). RECK is a glycoprotein that
downregulates matrix metalloproteinases that degrade extracellular
matrix (ECM) proteins and contribute to tumorigenesis. RECK is
inhibited during hypoxia through the activation of HIF-1α and miR372/373 (Loayza-Puch et al., 2010). Oncogenic RAS contributes to
this RECK inhibition through the upregulation of miR-21,
potentially strengthening this response or priming the cell for
survival during hypoxia (Loayza-Puch et al., 2010). Therefore,
oncogenic RAS equips the cell to deal with a hypoxic environment,
most notably by stabilizing HIF-1α and by converging on stressadaptive pathways that inhibit the tumor suppressor RECK.

Hypoxia describes a state of low or inadequate oxygen availability,
and can exist at the cell, tissue or organ level (Muz et al., 2015).
It often occurs as a result of reduced blood flow to a particular
region or because of the increased proliferation of cells within a
tissue, such as in a tumor, where highly proliferative cancer cells
consume more oxygen than normal cells and eventually outgrow
their initial supply. Cells undergoing hypoxia respond by stabilizing
hypoxia inducible factor 1 subunit alpha (HIF-1α), a transcription
factor responsible for the activation of multiple genes involved
in metabolism and angiogenesis, and vascular endothelial growth
factor (VEGF; also known as VEGFA), which promotes
angiogenesis to increase blood supply (Forsythe et al., 1996).
Cancer cells are notorious for generating a dysfunctional
vasculature through their stimulation of angiogenesis. Different
isoforms of VEGF exist, and their activation can lead to differential
vascularization patterns within a tumor (Yu et al., 2002). As this
vascularization changes, the distinct spatial regions of a tumor
experience periods of hypoxia and normoxia, leading to
environmental pressures that select for cells that can survive under
such conditions. In addition, hypoxia can induce epithelial-tomesenchymal transition, which enhances the invasive and
metastatic properties of cancer cells (Muz et al., 2015). Different
organs across the body have varying levels of oxygen that are
considered physiological, and each of these tissues experiences a
specific drop in oxygen levels when a tumor is present (Muz et al.,
2015). Therefore, in addition to the size of a tumor, the specific
tissue it forms in can affect the extent of hypoxia.
Oncogenic RAS-driven tumors experience hypoxic conditions
for the reasons described above, as oncogenic RAS increases cell
proliferation. There are also a variety of mechanisms that link

Adaptation to biomechanical stress

In order to survive, cells must be able to physically sense their
microenvironment and to adapt to changes or respond to signals
within that environment. There are a multitude of biomechanical
sensing molecules that integrate these external signals into cellular
responses, including cytoskeletal proteins, adhesion receptors and
ion channels (Daniel et al., 2013; Yao et al., 2014; Lim et al., 2018).
These sensing mechanisms can control cell shape, stiffness,
motility, proliferation, survival and fate in response to what they
sense within the surrounding environment. Changes in the
biomechanical sensing mechanisms of cells, as well as changes in
tension and homeostasis within a tissue overall, can be initiating
events in tumorigenesis (Fernández-Sánchez et al., 2015; Razzaghi
et al., 2012; Beverly et al., 2005; Pan et al., 2020).
Oncogenic RAS plays a role in the biomechanical properties of
cells, and assists with cell survival in a physically changing
microenvironment, such as during mitotic rounding and in
responses that involve cellular stiffness (Matthews et al., 2020;
Lin et al., 2015). For example, the expression of oncogenic HRAS
in Madin-Darby canine kidney-derived epithelial cells and in mouse
mammary gland epithelial cells, and the overexpression of
oncogenic KRAS in human pancreatic ductal cells, result in cell
softening compared to parental cell lines in vitro (Lin et al., 2015).
In addition, the proliferative capacity of cancer cell lines with
oncogenic KRAS was less affected than that of normal cells when
challenged with soft matrix growth conditions, suggesting that
oncogenic RAS can promote adaptation to biomechanical stress by
modulating cell stiffness (Lin et al., 2015).
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Oncogenic RAS has also been shown to directly affect the
composition of the microenvironment, aiding in both cancer cell
survival and metastasis. Transformation with oncogenic RAS leads
to the overexpression of tenascin-C, an ECM molecule that can
drive cancer progression (Maschler et al., 2004; Sun et al., 2018,
2019). Oncogenic RAS also promotes survival during ECM
detachment (Mason et al., 2016). ECM detachment induces
metabolic stress and the cell death program, anoikis, in normal
cells, but is an initiating step in the metastasis of cancer cells (Mason
et al., 2016; Schafer et al., 2009). When oncogenic RAS-expressing
cells undergo ECM detachment, RAS blocks anoikis via the
activation of serum/glucocorticoid-regulated kinase 1 (SGK-1) and
the downregulation of PH domain leucine-rich repeat protein
phosphatase (PHLPP; also known as PHLPP1), which inhibits
the activation of the p38 MAPK pathway and blocks its role in
anoikis, thus promoting survival and supporting metastasis (Mason
et al., 2016). Therefore, oncogenic RAS mediates the stiffnesssensing mechanisms of the cell, affects the matrix of the
surrounding microenvironment and favors cell survival during
metastasis.

mutant RAS isoforms (Grabocka and Bar-Sagi, 2016). Oncogenic
KRAS-mediated SG assembly depends on the production of the
lipid-signaling molecule 15-d-PGJ2, which occurs via the
RAS–ERK-mediated regulation of two key enzymes, COX-2 and
15-hydroxyprostaglandin dehydrogenase (HPGD) (Grabocka and
Bar-Sagi, 2016; Qiang et al., 2019). A particularly interesting aspect
of this oncogenic RAS-induced stress response is that it can occur in
a cell non-autonomous manner via the secretion of 15-d-PGJ2
(Grabocka and Bar-Sagi, 2016). Therefore, not only does oncogenic
RAS enhance stress tolerance in the cell in which it operates, but it
might also enhance the fitness of the surrounding cells in the
microenvironment (Grabocka and Bar-Sagi, 2016). SGs might thus
be a powerful RAS-induced stress-adaptive mechanism, as they are
a singular output that responds to multiple challenges that a RAStransformed cell faces. There is more to be uncovered about how
SGs function in the different stages of tumorigenesis and about the
specific mechanisms by which these granules combat the different
stresses. Deriving answers to these questions would constitute an
important step forward for the field, as such knowledge might aid in
the identification of therapeutic targets that could hinder this
pan-stress adaptation mechanism.

Adaptation to pan-stress stimuli
Stress adaptation in the persister cell phenotype

It is clear that multiple stress-adaptive pathways activated by
oncogenic RAS can promote survival in the face of transformationrelated stress. However, the way in which oncogenic RAS prepares
the cell to deal with external stress, such as from the tumor
microenvironment or chemotherapy, is also of great importance.
One of these RAS-driven stress-adaptive pathways has recently
been implicated in generating a stress-tolerant cell state, called a
cycling persister cell. Tolerant cells are described as cells that have a
reduced sensitivity to a particular drug or stress, whereas ‘persisters’
are cells that can enter into a dormant state to survive a particular
drug or stress (Sharma et al., 2010; Kurppa et al., 2020). Although
most persister cells remain dormant throughout a treatment, some
can re-enter the cell cycle during treatment, and thus pose an
immediate threat to a positive therapeutic outcome (Oren et al.,
2021). Cellular programs that contribute to a cycling, persister cell
phenotype during treatment have been described. The antioxidant
program’s genes have been shown to be more highly expressed
in cycling persister cell clones and to be targets of Nrf2 (Oren
et al., 2021). When ROS levels are reduced in persister cells,
through treatment with the scavenger molecule NAC or via the
overexpression of the antioxidant enzyme glutathione peroxidase 2,
the fraction of cycling persister cells increases by sixfold and
threefold, respectively. This finding indicates that the activation of
the antioxidant program might support the re-entry of persister cell
populations into the cell cycle (Oren et al., 2021). Interestingly,
oncogenic RAS increases ROS and Nrf2 expression levels, raising
the possibility that RAS might contribute to the cycling persister cell
population through this mechanism. The role of oncogenic RAS in
promoting the emergence of persister cells and the ability of these
cells to re-enter the cell cycle are important questions for future
research to address.
Overall, oncogenic RAS is apt at providing survival mechanisms
to combat its own stress induction, and may also contribute to an
overall stress-tolerant phenotype that promotes endurance in the
face of external stresses, such as chemotherapy. The following
sections will describe how several resistance mechanisms are borne
out of these oncogenic RAS-driven, stress-adaptive pathways,
suggesting that oncogenic RAS also functions on the axis of
external stress and chemoresistance.
6
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As described thus far, RAS-driven cancer cells are exposed to
a range of cellular stresses, and oncogenic RAS can respond to
these stresses in different ways by upregulating specific, stressadaptive mechanisms. Oncogenic RAS can also respond to
multiple stresses to enhance the overall stress tolerance of a cell,
and these mechanisms can be considered adaptations to pan-stress
stimuli. One of the major oncogenic, RAS-driven, pan-stress
adaptations is the upregulation of stress granules (SGs) (Fig. 2).
SGs are non-membranous cytoplasmic organelles that consist
of protein and RNA and that assemble in response to various
stress stimuli, such as hypoxia (Arimoto et al., 2008; Gottschald
et al., 2010), oxidative stress (Namkoong et al., 2018), DNA
damage (Byrd et al., 2016; Moutaoufik et al., 2014) and ER stress
(Namkoong et al., 2018). SGs confer cytoprotection and promote
survival, as evidenced by the fact that blocking SG formation
under stress reduces cell survival in human breast and colon
cancer cells in vitro (Arimoto et al., 2008; Grabocka and Bar-Sagi,
2016). SGs can directly oppose apoptosis by reducing ROS levels,
through the sequestration of mammalian target of rapamycin
complex 1 (mTORC1) via the spindle-associated protein astrin,
and through the sequestration of RACK1, a scaffolding protein
involved in the stress-activated MAPK-driven apoptotic response
(Arimoto et al., 2008; Takahashi et al., 2013; Thedieck et al.,
2013). Proteins that modulate SG assembly are upregulated in
many human cancer types, including cancer, colorectal and
prostate cancer, and sarcoma, and their expression levels often
correlate with a poorer prognosis in the patient (Somasekharan et al.,
2015; Sim et al., 2019; Li et al., 2020; Wang et al., 2021). In vivo,
SGs have been implicated in metastasis, as osteosarcoma cells
with knockdown of G3BP1 were associated with reduced levels
of lung metastases upon implantation in the kidney capsule,
compared to control osteosarcoma cells, which formed lung
metastases within 4-5 weeks of implantation (Somasekharan
et al., 2015).
Gain- and loss-of-function experiments in pancreatic and
colorectal cancer cell lines demonstrate that oncogenic KRAS
promotes SG formation as an adaptive mechanism to a variety of
tumor-associated stress stimuli (Grabocka and Bar-Sagi, 2016). The
induced expression of mutant HRAS also increases the SG-forming
capacity of cells, suggesting that this phenotype may translate across
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Stress adaptation in drug tolerance and tumor resistance

to that in mice with Atg7-expressing NSCLC. In addition, these
Atg7-deficient adenomas progressed into oncocytomas as opposed
to the adenocarcinomas seen in Atg7-expressing mice (Guo et al.,
2013). An attractive clinical strategy has been to inhibit autophagy
in such tumors; however, these monotherapies have ultimately
failed due to sustained disease progression (Wolpin et al., 2014).
More recently, data supporting the combined inhibition of
autophagy and various proteins in the oncogenic RAS pathway
has brought autophagy back into the spotlight (Bryant et al., 2019;
Kinsey et al., 2019; Leung et al., 2018; Lee et al., 2019). For
example, a recently identified small molecule, deltarasin, can
disrupt the association of the chaperone phosphodiesterase-δ
(PDEδ) with RAS, preventing PDEδ-mediated recruitment of
RAS to the plasma membrane and therefore its activation (Leung
et al., 2018). Deltarasin alone has a strong impact on tumor weight
in a lung cancer cell xenograft mouse model; the average tumor
weight of deltarasin-treated mice was 57% less than that of vehicletreated controls (Leung et al., 2018). This reduction in tumor size is
due to the induction of apoptosis caused by deltarasin-mediated
PDEδ inhibition. However, deltarasin treatment also leads to
protective autophagy, indicating that blocking autophagy might
enhance the efficacy of deltarasin (Leung et al., 2018). In support of
this, the anti-autophagic drug 3-MA more effectively induces
cancer cell death through apoptosis when combined with deltarasin
in vitro than when the cells are treated with deltarasin alone (Leung
et al., 2018). Similar results have also been reported when
autophagy inhibitors are combined with ERK1/2 inhibitors
(ERKi) in patient-derived pancreatic cancer xenograft models and
when used in triple combination with the BRAF and CRAF (also
known as RAF1) kinase inhibitors in KRAS-mutant cell lines
(Bryant et al., 2019; Lee et al., 2019). For example, one study has
shown that treating KRAS-mutant pancreatic cancer patient-derived
xenograft models with ERKi alone decreased tumor weight
twofold compared to that of vehicle-treated controls. By contrast,
when ERKi were combined with the autophagy inhibitor
hydroxychloroquine, they reduced tumor weight by approximately
sixfold (Bryant et al., 2019). These results indicate that, although

Unbiased drug screens for synthetic lethality and for other
multifaceted vulnerabilities of mutant RAS-driven cancer cells
have identified specific stress response proteins and entire stressadaptive pathways that, when inactivated, lead to increased cell
death, decreased tumorigenesis and decreased tumor progression
(Yang et al., 2019; Elliott et al., 2019; Luo et al., 2009). Findings
from these screens support the idea that stress-adaptive responses
are key contributors to the survival and resistance mechanisms of
RAS mutant cancer cells, and they provide evidence that the
targeting of these pathways can overcome resistance to the targeting
of RAS itself and of RAS pathway components. In this section,
we describe how the inhibition of stress-adaptive pathways might
challenge some of the current clinical problems concerning
resistance and we consider how therapy itself might induce
particular stresses that lead to novel stress-response vulnerabilities
in these tumors. Of note, oncogenic RAS cells also utilize adaptive
mechanisms to promote resistance to conventional chemotherapeutics,
which rely largely on DNA damage. The role of oncogenic RAS in
inducing the DNA damage response (DDR), in promoting
adaptation to DDR (Fig. 2), and the therapeutic strategies for
targeting this stress response have been reviewed in detail elsewhere
and are summarized in Table 1 (Grabocka et al., 2015; Reid et al.,
2014; Li et al., 2021b). Some characteristics of RAS mutant cells
that are pertinent to the response to classic chemotherapy and the
reported resistance mechanisms that utilize the cellular stress
response are summarized in Table 2.
Autophagy in drug response

The survival and progression of RAS mutant tumors has a complex
relationship with autophagy, and the dependence of these tumors on
autophagy has been well documented (Fig. 2) (Guo et al., 2011;
Poillet-Perez et al., 2015; Guo et al., 2016; Lock et al., 2014).
Autophagy-related 7 (ATG7) regulates autophagosome formation
and is required for autophagy to occur. In an oncogenic KRASdriven non-small cell lung cancer (NSCLC) mouse model, deleting
Atg7 specifically in tumor cells reduced the tumor burden compared

Table 1. Stress-adaptation to oncogenic RAS-induced DNA damage and resulting therapeutic strategies
DNA damage as a result of oncogenic
RAS

Adaptation to DNA damage

Potential therapeutic
strategies

References

Increased cell cycle entry and
changes in DNA replication timing
and activation

Sustained activity of the DNA damage response
(DDR) protein ATR
Sustained activity of wild-type RAS isoforms
in the cell
Upregulation of the glucose importer GLUT1

Inhibiting the DDR pathway
in combination with DNAdamaging agents

Murcia et al., 2019; Di Micco
et al., 2006; Gilad et al.,
2010; Schoppy et al., 2012
Grabocka et al., 2014

Inhibiting the DDR pathway
in combination with
metabolic inhibitors

Erber et al., 2019; Chen et al.,
2001

Resulting cellular characteristics
Increased levels of cytosolic DNA,
aberrant replication fork
progression, and increased
genomic instability
Activation of the DDR pathway,
leading to cell death or oncogeneinduced senescence

Increased dependence on ATR, as evidenced by
synthetic lethal knockout of ATR in RAStransformed cells

Di Micco et al., 2006; Al
Zubaidi et al., 2021; Gilad
et al., 2010

Increased sensitivity to DNA-damaging agents
when wild-type HRAS and NRAS are knocked
down in an oncogenic KRAS background
Increased dependence on metabolic processes,
such as glucose import, as the combined
inhibition of GLUT1 and either ATR or Chk1 (also
known as CHEK1) results in increased apoptosis
and a reduction in tumor volume in vivo

Di Micco et al., 2006; Bartkova
et al., 2006; Grabocka et al.,
2014
Erber et al., 2019
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Table 2. Stress-adaptive mechanisms in resistance to chemotherapy
Adaptive mechanisms to DNA-damaging agents

Adaptive mechanisms to replication stress-response inhibitors

References

KRAS mutant cells are less sensitive than KRAS wild-type cells
to DNA-damaging therapeutic agents

The RSK pathway has been implicated in stress tolerance and
survival, and oncogenic BRAF has been shown to utilize the
protein kinase RSK to activate mTOR
Increased expression of the receptor tyrosine kinase AXL has
been shown to contribute to resistance mechanisms in
replication stress response inhibition therapy

Al Zubaidi et al., 2021;
Romeo et al., 2013;
Lee et al., 2013
Fan et al., 2007, 2009;
Sen et al., 2017

oncogenic RAS induces autophagy, inhibiting the RAS pathway
can also lead to stress-adaptive autophagy. As such, pairing RAS
pathway inhibitors with autophagy inhibitors might push a cancer
cell towards programmed cell death instead of towards tumorpromoting autophagy responses.
In addition to the discovery that RAS pathway inhibition leads to
protective autophagy, new insights into the cellular response to
autophagy inhibitors have also come to light. A comprehensive
pharmacological screen recently identified replication response
inhibitors and the lysosome inhibitor chloroquine (CQ) as inducers
of synthetic lethality in PDAC cells (Elliott et al., 2019). CQ
has long been used to target lysosomal pathways, and inhibits the
final stage of the autophagy response. This study revealed that
reduced nucleotide biosynthesis in response to CQ treatment
leads to replication stress, rendering the cells vulnerable to
replication stress inhibitors. This phenotype was partially rescued
by supplementation with aspartate, a precursor for de novo
nucleotide synthesis (Elliott et al., 2019). These findings support
the notion that commonly used drugs, such as autophagy inhibitors
and membrane localization inhibitors of RAS, which have failed as
monotherapies against RAS-driven cancers, may induce particular
stress-adaptive responses that aid in a cancer’s survival and
resistance to such therapies. Identifying these secondary stress
responses may thus expose new targetable vulnerabilities while
blocking such responses may revive old therapeutic strategies.
Macropinocytosis in drug response

Oncogenic RAS can be a potent inducer of macropinocytosis,
depending on the type of oncogenic mutation involved (Fig. 2)
(Hobbs et al., 2020). However, the KRASG12R mutant, which is rare
in lung and colorectal cancer but more common in pancreatic cancer,
is dispensable for the characteristic upregulation of macropinocytosis,
as shown from the examination of ten different PDAC cell lines
(Hobbs et al., 2020). This mutation causes a structural change in the
protein that renders it incapable of binding to PI3Kα. A distinct PI3K
isoform, p110γ (also known as PIK3CG), compensates for this
loss and is responsible for the KRAS-independent upregulation of
macropinocytosis in these cells (Hobbs et al., 2020). KRASG12R
mutant cells are also more sensitive than KRASG12D/V cells to MEK/
ERK and PI3Kγ inhibition (Hobbs et al., 2020). This increased
sensitivity to PI3Kγ inhibition is most likely due to the inability of
KRASG12R to activate the PI3K pathway, indicating that different
RAS mutations might require specific therapeutic strategies to
effectively target stress-adaptive pathways. Future work should
include the investigation of compensatory mechanisms that result
from structural and functional differences between RAS mutant
subtypes, as this may help to lead to more individualized and effective
treatments for RAS-driven cancers.
Although RAS mutants might employ different mechanisms to
upregulate macropinocytosis, it is nevertheless elevated in most

Hu et al., 2019; Ren, 2018

RAS-driven cancers. One idea, therefore, is to use this enhanced
macropinocytosis as a system for delivering drugs, rather than
trying to inhibit it (Liu and Ghosh, 2019). RAS mutant cancer cells
preferentially scavenge lipids, glutamine and albumin through
macropinocytosis (Liu and Ghosh, 2019). For example, cross-linked
albumin nanoparticles are taken up in greater quantities by cells with
oncogenic KRAS than by their wild-type counterparts, and
colocalize with macropinosomes, indicating that macropinocytosis
was the uptake mechanism (Liu and Ghosh, 2019). This system
might therefore be used in the future to deliver drugs selectively to
KRAS mutant cells, potentially reducing toxicity to nontransformed cells and enhancing treatment efficacy.
Macropinocytosis aids in cancer anabolism and can directly
enhance resistance to anabolism-targeting therapies (Jayashankar
and Edinger, 2020). Anabolism is the biosynthesis of
macromolecules that support the metabolic needs of cells, and
common therapies that target anabolism include gemcitabine,
5-fluorouracil (5-FU), doxorubicin and γ-irradiation (Jayashankar
and Edinger, 2020). These drugs often kill cancer cells via necrosis,
which is a sudden and pro-inflammatory form of cell death in
which the contents of the dying cell are released into the
surrounding environment. When surrounding cells undergo
necrosis within the tumor microenvironment, RAS-mutant cancer
cells use macropinocytosis to take up the macromolecular end
products that form in the cellular debris to boost their nutrient
supply. The presence of such debris can also reduce the sensitivity
of macropinocytic oncogenic RAS cells to anabolism-targeting
therapies, as seen in oncogenic pancreatic cancer cells, which lose
their sensitivity to 5-FU when it is added alongside necrotic cellular
debris. These cells showed proliferation levels similar to those
of their untreated counterparts, whereas non-RAS mutant with
low macropinocytosis cells remained sensitive to 5-FU. 5-[N-ethylN-isopropyl] amiloride (EIPA) is a Na+/H+ exchanger inhibitor
that blocks macropinocytosis without affecting receptor-mediated
endocytosis. When cells were treated with 5-FU in the presence
of necrotic cell debris and EIPA, the aforementioned survival
advantage of RAS mutant cells was lost, indicating that
necrotic cellular debris uptake had occurred via macropinocytosis
(Jayashankar and Edinger, 2020). As the macropinocytosismediated uptake of macromolecules renders highly macropinocytic
cancer cells tolerant to anabolic-targeting therapies, therapies that
target both macropinocytosis and anabolic metabolism might
provide a promising combination by which to block resistance
mechanisms that emerge in the presence of anabolic-targeting
therapies.
ER stress adaptation in drug response

In support of the importance of the UPR stress response in cancer
cell stress tolerance and drug resistance, a recent drug-screening
study identified inhibitors of heat shock protein 90 (HSP90)
8
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REVIEW

Disease Models & Mechanisms (2022) 15, dmm049280. doi:10.1242/dmm.049280

proteins and AXL as the most detrimental to the growth of
chemoresistant/MEK inhibitor-resistant cell lines, compared to
therapy-naïve parental control cell lines (Yang et al., 2019). HSP90
proteins are chaperones responsible for proper protein folding,
trafficking and degradation, and are involved in regulating the UPR
response. AXL is a receptor tyrosine kinase that has been shown to
activate the RAS pathway. Inhibitors of HSP90 and MEK, when
combined, have strong anti-tumor effects in KRAS-mutant lung
cancer patient-derived xenograft mouse models and in NSCLC
xenograft mouse models, showing a three- to fourfold reduction in
tumor weight compared to that of vehicle-treated controls (Yang
et al., 2019). HSP90 inhibition has also been shown to preferentially
induce apoptosis in KRAS-mutant colon cancer cells in vitro and in
a colon cancer-derived xenograft model in nu/nu mice, indicating
that this vulnerability might translate across different RAS-mutant
tumor types (Wang et al., 2016). Targeting the UPR pathway can
also block another stress-adaptive mechanism, protective
autophagy, and can overcome resistance in melanoma cell lines,
making the blocking of the UPR stress response an even more
attractive approach (Ma et al., 2014). In the first example, protective
autophagy was induced in response to BRAF inhibitors and blocked
by the addition of a PERK inhibitor, leading to increased cell death.
These findings suggest that blocking the UPR stress response might
be an effective way to overcome this resistance mechanism (Ma
et al., 2014). The same study also shows how stress-adaptive
pathways are often interlinked, and how identifying and targeting
the most critical mechanism for a cell could reduce its overall stress
tolerance. In addition, it might be possible to identify which patients
would most benefit from UPR-based combinatorial therapies by
assessing their levels of UPR activity (Yang et al., 2019). Thus,
stress-adaptive pathways could be used as biomarkers to predict
patient responses to specific stress-targeting therapies and to predict
which resistance mechanisms might emerge by profiling the stressadaptive responses that are already heightened at the start of
treatment.

(Chen et al., 2019). Given that SGs are a mechanism of resistance
induced by both oncogenic KRAS and chemotherapy, with the
former also creating resistance in a paracrine manner in surrounding
tissue, SG-targeting agents are likely to provide potent therapeutics
for treating oncogenic RAS-driven tumors.
Other proteins or pathways might also respond to a multitude of
RAS-induced stresses. One such example has been identified in the
investigation of resistance mechanisms that accompany treatment
with EGFR inhibitors. Oncogenic RAS colorectal cancer cells that
are sensitive to EGFR-targeting antibodies undergo apoptosis
through the p73-dependent transcriptional activation of the BH3only protein PUMA (also known as BBC3); when these cells
acquire resistance, they exhibit a reduction in PUMA expression
(Knickelbein et al., 2018). PUMA induces apoptosis in response to
ER and genotoxic stress, and to deregulated oncogenic signaling
(Yu and Zhang, 2008). Thus, PUMA loss might be a stress-adaptive
mechanism that promotes survival in the context of many oncogenic
RAS-induced stresses. The reactivation of PUMA, when combined
with RAS pathway inhibition, might produce a synergistic effect
that promotes apoptosis and reduces the survival of RAS-driven
tumor cells. Another potential strategy would be to induce PUMA
alongside inhibiting autophagy, because autophagy protects against
many oncogenic RAS-induced stresses. Overall, it is apparent that
some oncogenic RAS-induced, and therapy-derived, stress-adaptive
mechanisms lead to a stress-tolerant state that mitigates against a
plethora of RAS-induced stresses. As such, the identification and
targeting of such mechanisms might be the most effective way to
enhance the efficacy of RAS-targeted therapies.

As previously described, oncogenic KRAS signals upregulate SG
formation via the production of the signaling molecule 15-d-PGJ2.
This process promotes survival in response to a variety of RAS- and
chemotherapy-induced stresses. For example, in oncogenic KRASexpressing HeLa cells, levels of oxidative stress-induced apoptosis
increased following the addition of the SG inhibitor emetine
(Grabocka and Bar-Sagi, 2016). By contrast, apoptosis levels in
wild-type HeLa cells remained unaffected by emetine treatment,
indicating that SGs play a specific role in survival during stress in
oncogenic KRAS-driven cells (Grabocka and Bar-Sagi, 2016).
When SG formation was blocked using a COX-1/2 inhibitor in
oncogenic KRAS-driven colon cancer cells, the cells also showed
increased sensitivity to the chemotherapeutic drug oxaliplatin. This
effect functioned at a paracrine level, consistent with the paracrine
induction of SGs by oncogenic KRAS (Grabocka and Bar-Sagi,
2016). Multiple anti-cancer drugs have been shown to induce SGs,
including 5-FU, lapatinib, sorafenib, oxaliplatin, bortezomib and
selenite, to name a few (Kaehler et al., 2014; Adjibade et al., 2020;
Hu et al., 2021). One study reported that 5-FU treatment of
colorectal cancer cell lines in vitro increased their expression of
Musashi-1, a colon stem cell marker and RNA-binding protein,
which contributed to the formation of anti-apoptotic SGs and to the
population of CD44+ stem cells (Chiou et al., 2017). In ovarian
carcinoma cells, the inhibition of Musashi-1 blocked paclitaxel
resistance, implicating this SG-promoting protein in drug resistance

The mechanisms that underlie resistance to KRASG12C inhibitors in
lung and other types of cancer are at an early stage of investigation.
Thus far, a variety of resistance mechanisms have been described, but
most seem to share the common end result of reactivating the MAPK
pathway (Ryan et al., 2020; Xue et al., 2020; Tanaka et al., 2021),
such as acquired mutations in BRAF, NRAS, MAP2K1 (MEK1) and
KRAS itself (Tanaka et al., 2021). These acquired KRAS mutations
include other common variants in KRAS that are seen across mutant
KRAS-driven cancers, such as the G13D and G12V substitutions, as
well as a novel mutation in residue 96 (KRASY96D) that are yet to be
documented in the clinic (Tanaka et al., 2021). Unfortunately, many
of these acquired resistance mechanisms were identified from the
biopsies of a single patient, indicating that resistance to KRASG12C
inhibitors is quite heterogeneous. This would suggest that there
may be an even greater level of heterogeneity within the patient
population. Therefore, there exists a great need for a more generalized
approach to blocking the reactivation of MAPK signaling during
treatment with KRASG12C inhibitors. Because many of the stressadaptive mechanisms described above are activated through MAPK
signaling, it is likely that they also play a role in resistance to
KRASG12C inhibitors. Thus, investigating the role of stress-adaptive
mechanisms in this process may provide insight into strategies to
prevent and overcome emerging resistance to KRASG12C inhibitors.
Overall, as new therapies arise that aim to target oncogenic RAS, the
integrated stress response of the cell should be considered in terms of
investigating resistance mechanisms, combining therapies and
identifying biomarkers, in order to block resistance and enhance
patient outcomes.
Conclusions

The findings we discuss here indicate that although tumor resistance
is multifactorial, stress-adaptive mechanisms might provide key
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targetable vulnerabilities in RAS-driven tumors. From a therapeutic
perspective, the combinatorial inhibition of RAS, its downstream
signaling pathways, multiple stress-response pathways and/or
adaptive mechanisms to pan-stress stimuli, provide a promising
approach to the treatment of these tumors. Perhaps, these
combinations could be stratified based on which stress-response
pathways are known to be activated among different RAS-driven
cancers or as a result of RAS-targeted therapies. The upregulation of
stress-response pathways might also be used as biomarkers of
resistance, as well as of responses to specific therapies. Therapies
that have previously failed in the clinic might also regain clinical
traction, particularly once the stress-adaptive pathways or proteins
that aid in a specific resistance mechanisms to a therapy are
identified. It is exciting to consider the possibility that RAS-driven
stress-adaptive mechanisms could provide a promising new avenue
of investigation for therapeutics that alone or in combinations could
successfully treat RAS-driven cancers.
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